FACULTY
|
 Patrick
J. Boyle, MD
University of New Mexico School of Medicine Albuquerque, New Mexico
|
John B. Buse, MD, PhD, CDE
University of North Carolina School of Medicine Chapel Hill, North Carolina
|
|
 Steven
V. Edelman, MD
University of California San Diego
San Diego, California
|
 Vivian
A. Fonseca, MD, MRCP
Tulane University Health Sciences Center
New Orleans, Louisiana
|
|
 Davida
F. Kruger, MSN, APRN-BC, BC-ADM Henry Ford Health System
Detroit, Michigan
|
 Catherine L. Martin, MS, APRN, BC-ADM, CDE
University of Michigan Health System
Ann Arbor, Michigan
|
|
 Bernard
Zinman, MDCM, FRCP(C), FACP
Mount Sinai Hospital and University
of Toronto
Toronto, Ontario, Canada
|
|
| |
Patrick J. Boyle, MD
Patrick J. Boyle, MD, is Professor of Medicine at the University of New Mexico
School of Medicine in Albuquerque. Dr. Boyle received his medical degree from
Oregon Health Sciences University in Portland. His postgraduate training
included an internship and chief residency at Oregon Health Sciences University
and a fellowship in metabolism and endocrinology at Washington University in
St. Louis.
Dr. Boyle is certified by the American Board of Internal Medicine in
endocrinology, diabetes,
and metabolism. His research interests include diabetes and glucose metabolism;
he is the
author or coauthor of articles, abstracts, and reviews that have appeared in New
England Journal
of Medicine, Diabetes, Diabetes Care, Annals of Internal Medicine, and
others. Dr. Boyle has
written books and book chapters that include 101 Tips for Improving Your Blood
Sugar, The
Clinical Practice of Diabetes Mellitus: Hypoglycemia, and Interrelationships
Between the Central Nervous System and Peripheral Glucose
Metabolism. He has served on the editorial board of Diabetes and
as a reviewer for such journals as New England Journal of Medicine, Journal of
the American Medical Association, Diabetes, Diabetes Care, Journal of Clinical
Investigation, American Journal of Physiology, and Diabetologia.
Dr. Boyle's professional affiliations include service on the Board of Directors
of the American
Diabetes Association and Program Director of the General Clinical Research
Center at the
University of New Mexico, funded by the National Institutes of Health. His
honors include the
National Diabetes Disease Management Leadership Award and the 1996–1997 Faculty
Teaching Excellence Award.
DISCLOSURE
No disclosure received to date.
Return to Top
|
| |
John B. Buse, MD, PhD, CDE
John B. Buse, MD, PhD, CDE, is Associate Professor, Director of the
Diabetes Care Center, and Chief of the Division of General Medicine and
Clinical Epidemiology at the University of North Carolina School of Medicine
in Chapel Hill. He also sees patients at the Salem Center in Winston-Salem,
North Carolina.
Dr. Buse received his medical degree and doctorate of philosophy from Duke
University in
Durham, North Carolina. He completed his dissertation research at the Joslin
Diabetes Center in Boston. He was intern, resident, and chief resident in the
Department of Medicine and subsequently a fellow and faculty member in the
Section of Endocrinology at the University of Chicago. In 1994,
he joined the faculty at the University of North Carolina.
Dr. Buse is certified by the American Board of Internal Medicine and the
National Certification
Board for Diabetes Educators. He is a member of the American Diabetes
Association, the
American Association of Clinical Endocrinologists, the American College of
Physicians, The Endocrine Society, and the Society of General Internal
Medicine. He has been the principal investigator on numerous grants and has
published manuscripts and reviews in such journals
as Diabetes, Diabetes Technology and Therapeutics, and Journal of
Clinical Endocrinology
and Metabolism.
DISCLOSURE
Dr. Buse has received honoraria related to formal advisory
activities from Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; BD; Merck
& Co., Inc.; and Bristol-Myers Squibb Company. He has received grant
support related to research activities from Pfizer Inc.; Novartis; DexCom; BD;
and Bristol-Myers Squibb Company. Dr. Buse owns significant holdings in Insulet
Corporation.
Return to Top
|
| |
Steven V. Edelman, MD
Steven V. Edelman, MD, is Professor of Medicine in the Division of
Endocrinology and Metabolism at the University of California San Diego.
He is also Director of the Diabetes Care Clinic at the Veterans Affairs
Medical Center in San Diego.
Dr. Edelman received his medical degree from the University of California at
Davis. His postgraduate training included a residency in internal medicine at
UCLA-San Fernando Valley; a clinical fellowship in diabetes and metabolism at
the Joslin Clinic; a fellowship in endocrinology and metabolism at the Lahey
Clinic in Burlington, Massachusetts; and a research fellowship in diabetes and
metabolism at the University of California San Diego. Dr. Edelman is certified
in internal medicine, metabolism, diabetes, and endocrinology.
Dr. Edelman is founder and executive director of Taking Control of Your
Diabetes (TCOYD), a
series of educational and motivational conferences and health fairs for people
with diabetes. He
has written numerous books and publications including articles and abstracts
that have been published in such journals as American Journal of Physiology,
Diabetes, and Journal of Clinical Endocrinology and Metabolism.
Dr. Edelman is a reviewer for several journals including Annals of Internal
Medicine, Journal of
Clinical Investigation, and Journal of Clinical Endocrinology and
Metabolism. His honors include
being valedictorian of his medical school graduating class; Alumnus Award from
the University of California Davis School of Medicine; and Chief Resident's
Teacher of the Year Award from the University of California San Diego.
DISCLOSURE
Dr. Edelman has received honoraria related to
formal advisory and speaker-bureau activities and
the development of educational materials from Aventis; Eli Lilly and Company;
Novo Nordisk; GlaxoSmithKline; Takeda Pharmaceuticals North America, Inc.; and
Amylin Pharmaceuticals, Inc. He has also received grant support related to
research activities from Amylin Pharmaceuticals, Inc.
Return to Top
|
| |
Vivian A. Fonseca, MD, MRCP
Vivian A. Fonseca, MD, MRCP, is Professor of Medicine and Adjunct Professor of
Pharmacology at Tulane University Health Sciences Center in New Orleans, where
he holds the Tullis-Tulane Alumni Chair in Diabetes. He is also Medical
Director of Tulane Hospital Diabetes Education Program.
Dr. Fonseca received his medical degree from Bombay University in India.
His postgraduate training included an internship at King Edward Memorial
Hospital in Bombay and a research fellowship at Royal Free Hospital in London.
Dr. Fonseca is certified by the American Board of Internal Medicine and
American Board of Endocrinology, Metabolism, and Diabetes. He is a fellow of
the American College of Physicians and the American Association of Clinical
Endocrinologists.
Dr. Fonseca has written abstracts, reviews, and articles for Diabetes Care,
Metabolism, The Endocrinologist, New England Journal of Medicine, and The
Lancet. In addition, he has lectured nationally and internationally.
Dr. Fonseca is a member of several professional organizations
including the American Heart Association, The Endocrine Society, and the
American Diabetes Association, for which he has served on the Board of
Directors.
DISCLOSURE
Dr. Fonseca has disclosed that he has no significant relationships with the
grantors, Amylin Pharmaceuticals, Inc., Eli Lilly and Company,
or any other commercial company whose products
and services are discussed.
Return to Top
|
Davida F. Kruger, MSN, APRN-BC, BC-ADM
Davida F. Kruger, MSN, APRN-BC, BC-ADM, is a certified nurse practitioner at
the Henry Ford Health System in Detroit, Michigan. Ms. Kruger serves on the
American Diabetes Association fund-raising committee. She is past chair of the
American Diabetes Association Research Foundation and has served on the
Research Policy Committee. She is a past president of the Health Care and
Education Committee of the American Diabetes Association and was Associate
Editor of Diabetes Spectrum.
Ms. Kruger received her undergraduate degree in nursing from Boston College and
her master of science in nursing degree from Wayne State University in Detroit.
She is board certified by the American Nurses Association Credentialing Center
in both primary-care and advanced diabetes management. She is a member of Sigma
Theta Tau National Honor Society.
Ms. Kruger has written articles and book chapters on diabetes research and
clinical practice. Her work has appeared in prominent publications including Conn's
Current Therapy, Diabetes, Diabetes Care, and New
England Journal of Medicine. She is a member of several professional
organizations including the American Diabetes Association, the American
Association of Diabetes Educators, and the American Nurses Association. Her
honors include the Florence Nightingale Award.
DISCLOSURE
Ms. Kruger has received honoraria related to formal advisory
activities from Novo Nordisk; Abbott Laboratories; Aventis; Takeda
Pharmaceuticals North America, Inc.; Consortium for Appropriate Dispute
Resolution in Special Education; DexCom; and Home Diagnostics, Inc. Ms. Kruger
has received honoraria related to speaker-bureau activities from Novo Nordisk;
Aventis; Ross Laboratories; and Amylin Pharmaceuticals, Inc. She has also
received honoraria related to the development of educational materials from
Amylin Pharmaceuticals, Inc. and Abbott Laboratories.
Return to Top
|
| |
Catherine L. Martin, MS, APRN, BC-ADM, CDE
Cochair of DHEC
Catherine L. Martin, MS, APRN, BC-ADM, CDE, is Trial Coordinator for the
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions
and Complications (DCCT/EDIC) study. She is also a Clinical Care Coordinator
for the Intensive Insulin Management Program at the University of Michigan
Health System, Ann Arbor. Her past positions include Director of the Diabetes
Disease Management Pilot Project and Clinical Study Coordinator at the
University of Michigan Health System.
Ms. Martin received her master's degree from the University of Michigan in Ann
Arbor. She is a registered nurse, a certified diabetes educator, and a member
of several professional organizations including the American Nurses
Association, the Michigan Nurses Association, the American Association of
Diabetes Educators, and the American Diabetes Association.
Ms. Martin has written abstracts, reviews, and articles for Diabetes Care, New
England Journal of Medicine, and Diabetes
and has lectured nationally on such topics as peripheral neuropathy and
intensive insulin therapy for patients with diabetes. Her honors include the
Julio Santiago Diabetes Research Clinic Achievement Award and the R. Faye
McCain Memorial Award for Leadership and Scholarly Excellence in Medical
Surgical Nursing. DISCLOSURE
Ms. Martin has received honoraria related to speaker-bureau
activities from Amylin Pharmaceuticals, Inc. and Eli Lilly and Company.
Return to Top
|
| |
Bernard Zinman, MDCM, FRCP(C), FACP
Bernard Zinman, MDCM, FRCP(C), FACP, is
Director of the Leadership
Sinai Centre for Diabetes and holds the Sam and Judy Pencer Family Chair
in Diabetes Research at Mount Sinai Hospital and the University of Toronto,
Canada. He is Professor of Medicine at the University of Toronto and Senior
Scientist at the Samuel Lunenfeld Research Institute, Mount Sinai Hospital.
Dr. Zinman is the principal investigator of the University of Toronto Centre
for
the DCCT/EDIC study.
Dr. Zinman has written articles in national and international journals, book
chapters, and editorials.
He is the recipient of numerous awards, including the Charles H. Best Medal for
Distinguished Service in the Cause of Diabetes (awarded by the DCCT
investigators), the Alois Beringer Lecture Award, and the Frederick G. Banting
and Gerald Wong Awards of the Canadian Diabetes Association. In November 2000,
Dr. Zinman chaired the scientific program committee of the
17th International Diabetes Federation Congress held in Mexico City.
DISCLOSURE
Dr. Zinman has received honoraria related
to formal advisory activities from Eli Lilly and Company; Amylin
Pharmaceuticals, Inc.; Novartis; and ConjuChem, Inc. He has also received
honoraria related to speaker-bureau activities from Eli Lilly and Company and
Amylin Pharmaceuticals, Inc. and grant support related to research activities
from Novartis and Eli Lilly and Company.
Return to Top
|
|
|
|
|
